Market Overview

Seattle Genetics Presents Interim Phase 1 from Novel Antibody-Drug Conjugate SGN-CD19A at ASH 2013

Seattle Genetics (Nasdaq: SGEN) today presented interim phase 1 clinical data from SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, including acute lymphoblastic leukemia (ALL), at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, Louisiana, December 7-10, 2013. SGN-CD19A is an ADC targeting CD19, a protein expressed uniformly on almost all B-cell malignancies. ADCs are monoclonal antibodies that are designed to selectively deliver cytotoxic agents to tumor cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing antitumor activity.#ASH13

See full press release

Posted-In: News Guidance Management

 

Related Articles (SGEN)

Around the Web, We're Loving...

Get Benzinga's Newsletters